Re: Soumyajit Roy, Yilun Sun, Scott C. Morgan, et al. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. Eur Urol 2023;83:571-9.

作者信息

Li Xiao, Xu Zicheng, Qi Feng

机构信息

Department of Urologic Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.

出版信息

Eur Urol. 2024 Jan;85(1):e14. doi: 10.1016/j.eururo.2023.06.034. Epub 2023 Aug 16.

DOI:10.1016/j.eururo.2023.06.034

PMID:37596190

Abstract

摘要

相似文献

Re: Soumyajit Roy, Yilun Sun, Scott C. Morgan, et al. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. Eur Urol 2023;83:571-9.

Eur Urol. 2024 Jan;85(1):e14. doi: 10.1016/j.eururo.2023.06.034. Epub 2023 Aug 16.

Reply to Xiao Li, Zicheng Xu, and Feng Qi's Letter to the Editor re: Soumyajit Roy, Yilun Sun, Scott C. Morgan, et al. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. Eur Urol 2023;83:571-9.

Eur Urol. 2024 Jan;85(1):e12-e13. doi: 10.1016/j.eururo.2023.08.005. Epub 2023 Aug 16.

Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial.局部治疗在先对转移性去势抵抗性前列腺癌一线抗雄激素受体轴靶向治疗反应的影响：COU-AA-302 试验的二次分析。

Eur Urol. 2023 Jun;83(6):571-579. doi: 10.1016/j.eururo.2023.02.017. Epub 2023 Mar 7.

Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.既往内分泌治疗对醋酸阿比特龙治疗转移性去势抵抗性前列腺癌临床疗效的影响：3期随机研究的事后分析

Eur Urol. 2016 May;69(5):924-32. doi: 10.1016/j.eururo.2015.10.021. Epub 2015 Oct 24.

Re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30.回复：亚历山德罗·夏拉、佩尔·安德斯·亚伯拉罕松、毛里齐奥·布劳西等。前列腺癌间歇性雄激素剥夺疗法：聚焦于3期试验的批判性综述。《欧洲泌尿外科杂志》2013年；64卷：722 - 730页

Eur Urol. 2014 Apr;65(4):e56. doi: 10.1016/j.eururo.2013.12.016. Epub 2013 Dec 21.

Reply to Bernard Tombal's letter to the editor re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30.对伯纳德·通巴尔致编辑的信的回复，信的主题为：亚历山德罗·夏拉、佩尔·安德斯·亚伯拉罕松、毛里齐奥·布劳西等人所著《前列腺癌的间歇性雄激素剥夺疗法：聚焦于3期试验的批判性综述》。《欧洲泌尿外科杂志》2013年；第64卷：722 - 730页

Eur Urol. 2014 Apr;65(4):e57. doi: 10.1016/j.eururo.2013.12.015. Epub 2013 Dec 21.

Re: Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium. Eur Urol. 2022;82:106-14.

Eur Urol. 2022 Sep;82(3):e80-e81. doi: 10.1016/j.eururo.2022.05.034. Epub 2022 Jun 7.

Re: Heng Li, Yucong Zhang, Dong Li, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. Eur Urol 2021;79:879-86 AR-V7 is Rare in Hormone-sensitive Prostate Cancer: AR-V7 is Rare in Hormone-sensitive Prostate Cancer.

Eur Urol. 2022 Nov;82(5):e135-e136. doi: 10.1016/j.eururo.2022.06.028. Epub 2022 Aug 26.

Re: Liam Bourke, Stephen Gilbert, Richard Hooper, et al. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol 2014;65:865-72; Re: Daniel A. Galvão, Nigel Spry, James Denham, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol 2014;65:856-64; Re: Nancy L. Keating, Pang-Hsiang Liu, A. James O'Malley, Stephen J. Freedland, Matthew R. Smith. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 2014;65:816-24; Re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 2014;65:704-9.回复：利亚姆·伯克、斯蒂芬·吉尔伯特、理查德·胡珀等人。生活方式改变对接受晚期前列腺癌长期雄激素剥夺治疗的久坐男性特定疾病生活质量的改善作用：一项随机对照试验。《欧洲泌尿外科杂志》2014年；65：865 - 872；回复：丹尼尔·A·加尔瓦奥、奈杰尔·斯普里、詹姆斯·德纳姆等人。一项针对接受过雄激素抑制和放疗的前列腺癌男性进行的为期一年的多中心随机对照试验，该试验以运动训练改善身体机能为目标（来自TROG 03.04 RADAR研究）。《欧洲泌尿外科杂志》2014年；65：856 - 864；回复：南希·L·基廷、刘庞祥、A·詹姆斯·奥马利、斯蒂芬·J·弗里德兰、马修·R·史密斯。前列腺癌男性糖尿病患者中的雄激素剥夺治疗与血糖控制。《欧洲泌尿外科杂志》2014年；65：816 - 824；回复：克里斯蒂娜·G·耶斯佩森、梅特·诺尔加德、迈克尔·博勒。前列腺癌治疗中的雄激素剥夺治疗与心肌梗死和中风风险：一项基于丹麦全国人口的队列研究。《欧洲泌尿外科杂志》2014年；65：704 - 709。

Eur Urol. 2014 Sep;66(3):e51-2. doi: 10.1016/j.eururo.2014.04.018. Epub 2014 May 10.

Re: Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.015.回复：纳迪尔·纳库齐、西尔维斯特·勒穆莱克、劳伦斯·阿尔比热斯等。在多西他赛治疗后进展且随后接受新型雄激素受体途径靶向治疗的患者中，卡巴他赛仍具有活性。《欧洲泌尿外科杂志》。即将发表。http://dx.doi.org/10.1016/j.eururo.2014.04.015 。

Eur Urol. 2014 Oct;66(4):e71-2. doi: 10.1016/j.eururo.2014.06.038. Epub 2014 Jul 8.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验